# Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT06001788** · PHASE1 · RECRUITING · sponsor: **Kura Oncology, Inc.** · enrollment: 171 (estimated)

## Conditions studied

- AML
- AML With Mutated NPM1
- Hematologic Malignancy
- KMT2Ar
- NPM1 Mutation
- MLL Rearrangement
- Leukemia
- Acute Myeloid Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Acute Leukemia
- Neoplasms by Histologic Type

## Interventions

- **DRUG:** Ziftomenib
- **DRUG:** Fludarabine
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine
- **DRUG:** Gilteritinib
- **BIOLOGICAL:** Granulocyte colony-stimulating factor

## Key facts

- **NCT ID:** NCT06001788
- **Lead sponsor:** Kura Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-22
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 171 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001788, "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06001788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*